James D Palmer, MD
Ophthalmology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 33
- 9 carriers
- Offices
- 4
Offices
4 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
33 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Palmer’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
33 of 33 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G26383 · Current
Licensed to practise in California · since 1974 · expires 2027-01-31 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$3,234,949
Medicare paid this office $3,234,949 for 1,013 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 151 | $1,331,544 | None |
| Injection, aflibercept, 1 mg | 216 | $896,745 | None |
| Injection, aflibercept hd, 1 mg | 71 | $383,857 | None |
| Injection of drug into eye | 366 | $168,840 | $112 |
| Imaging of retina | 904 | $93,032 | $39 |
See all 15 services
| Injection, faricimab-svoa, 0.1 mg | 151 | $1,331,544 | None |
| Injection, aflibercept, 1 mg | 216 | $896,745 | None |
| Injection, aflibercept hd, 1 mg | 71 | $383,857 | None |
| Injection of drug into eye | 366 | $168,840 | $112 |
| Imaging of retina | 904 | $93,032 | $39 |
| Return visit (30+ min) | 353 | $79,464 | $121 |
| Established patient complete exam of visual system | 523 | $56,914 | $107 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 188 | $37,399 | $163 |
| Short return visit (20+ min) | 318 | $32,307 | $74 |
| Established patient problem focused exam of visual system | 226 | $21,306 | $80 |
| New patient visit (45+ min) | 80 | $11,512 | $144 |
| New patient complete exam of visual system | 85 | $11,221 | $132 |
| Photography of the retina | 119 | $4,994 | $34 |
| 2d ultrasound scan of eye tissue and structures | 25 | $1,597 | $47 |
| Extended exam of the back part of the eye with retinal drawing | 17 | $348 | $20 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
1,013 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 25% · Women 56% · Also on Medicaid 31% · Health risk score 1.44. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 40% · Chronic kidney disease 28% · Coronary heart disease 23% · Heart failure 16% · Atrial fibrillation 16% · Cancer 14% · Depression 11% · COPD 10% · Dementia 7% · Stroke 7%.
The office billed $9,616,471, Medicare allowed $4,123,832 and paid $3,234,949; for 59,119 services of 51 kinds; $2,661,895 of it was for drugs given in the office and $573,054 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,013 | 59,119 | 78 | 1.44 | $9,616,471 | $3,234,949 |
| 2023 | 981 | 34,678 | 78 | 1.38 | $8,829,540 | $3,065,211 |
| 2022 | 894 | 13,829 | 78 | 1.38 | $8,585,745 | $3,061,058 |
| 2021 | 1,012 | 14,003 | 78 | 1.36 | $9,388,609 | $3,523,726 |
| 2020 | 909 | 13,803 | 78 | 1.46 | $8,852,868 | $3,298,751 |
| 2019 | 1,042 | 15,238 | 78 | 1.45 | $8,441,926 | $3,227,313 |
| 2018 | 1,020 | 12,618 | 77 | 1.40 | $6,575,674 | $2,582,029 |
| 2017 | 981 | 11,589 | 77 | 1.53 | $5,269,641 | $2,157,988 |
| 2016 | 953 | 11,658 | 78 | 1.54 | $3,832,633 | $1,977,921 |
| 2015 | 946 | 11,228 | 78 | 1.49 | $3,394,830 | $1,793,929 |
| 2014 | 972 | 13,015 | 78 | 1.44 | $3,086,184 | $1,765,522 |
| 2013 | 968 | 14,544 | 78 | 1.43 | $3,369,805 | $2,038,562 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Injection, aflibercept, 1 mg | 295 | $1,698,393 | None |
| Injection, faricimab-svoa, 0.1 mg | 120 | $702,897 | None |
| Injection of drug into eye | 378 | $167,637 | $106 |
| Imaging of retina | 875 | $89,752 | $37 |
| Injection, ranibizumab, 0.1 mg | 25 | $73,498 | None |
| Return visit (30+ min) | 327 | $57,579 | $103 |
| Established patient complete exam of visual system | 497 | $52,943 | $104 |
| Short return visit (20+ min) | 383 | $47,576 | $79 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 183 | $27,328 | $127 |
| Established patient problem focused exam of visual system | 209 | $16,925 | $69 |
| New patient complete exam of visual system | 118 | $15,574 | $132 |
| New patient visit (45+ min) | 74 | $10,535 | $142 |
| Photography of the retina | 109 | $4,593 | $32 |
| Compounded drug, not otherwise classified | 13 | $1,603 | None |
| 2d ultrasound scan of eye tissue and structures | 19 | $1,025 | $43 |
| Extended exam of the back part of the eye with retinal drawing | 31 | $559 | $17 |
2022: 16 services
| Injection, aflibercept, 1 mg | 307 | $2,118,312 | None |
| Injection, ranibizumab, 0.1 mg | 61 | $346,325 | None |
| Injection of drug into eye | 359 | $175,258 | $105 |
| Imaging of retina | 814 | $89,514 | $37 |
| Injection, faricimab-svoa, 0.1 mg | 23 | $71,620 | None |
| Established patient problem focused exam of visual system | 461 | $56,508 | $79 |
| Established patient complete exam of visual system | 529 | $54,852 | $101 |
| Return visit (30+ min) | 229 | $30,355 | $99 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 186 | $25,489 | $119 |
| Short return visit (20+ min) | 157 | $16,342 | $84 |
| New patient visit (45+ min) | 114 | $14,672 | $129 |
| New patient complete exam of visual system | 29 | $3,962 | $137 |
| Photography of the retina | 88 | $3,828 | $33 |
| Compounded drug, not otherwise classified | 12 | $2,078 | None |
| Extended exam of the back part of the eye with retinal drawing | 48 | $1,087 | $22 |
| 2d ultrasound scan of eye tissue and structures | 16 | $941 | $43 |
2021: 15 services
| Injection, aflibercept, 1 mg | 315 | $2,362,932 | None |
| Injection, ranibizumab, 0.1 mg | 74 | $528,190 | None |
| Injection of drug into eye | 397 | $203,296 | $108 |
| Established patient problem focused exam of visual system | 616 | $119,146 | $84 |
| Imaging of retina | 852 | $98,217 | $38 |
| Established patient complete exam of visual system | 534 | $47,723 | $85 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 199 | $26,906 | $117 |
| New patient visit (45+ min) | 184 | $25,749 | $140 |
| Return visit (30+ min) | 155 | $19,205 | $122 |
| Photography of the retina | 227 | $9,229 | $35 |
| Compounded drug, not otherwise classified | 21 | $4,437 | None |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 11 | $3,188 | $245 |
| Short return visit (20+ min) | 30 | $2,933 | $84 |
| Extended exam of the back part of the eye with retinal drawing | 99 | $2,581 | $23 |
| 2d ultrasound scan of eye tissue and structures | 27 | $1,434 | $42 |
2020: 13 services
| Injection, aflibercept, 1 mg | 271 | $2,031,722 | None |
| Injection, ranibizumab, 0.1 mg | 84 | $656,980 | None |
| Injection of drug into eye | 370 | $174,083 | $96 |
| Established patient complete exam of visual system | 741 | $132,317 | $100 |
| Imaging of retina | 732 | $87,722 | $37 |
| Established patient problem focused exam of visual system | 354 | $86,976 | $81 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 188 | $23,291 | $100 |
| New patient visit (45+ min) | 170 | $22,187 | $131 |
| Photography of the retina | 258 | $13,065 | $40 |
| Compounded drug, not otherwise classified | 32 | $9,006 | None |
| Extended exam of the back part of the eye with retinal drawing | 89 | $2,602 | $23 |
| 2d ultrasound scan of eye tissue and structures | 27 | $1,711 | $48 |
| Short return visit (20+ min) | 14 | $1,125 | $70 |
2019: 13 services
| Injection, aflibercept, 1 mg | 244 | $1,765,941 | None |
| Injection, ranibizumab, 0.1 mg | 114 | $774,400 | None |
| Injection of drug into eye | 379 | $170,591 | $95 |
| Established patient complete exam of visual system | 862 | $160,174 | $102 |
| Imaging of retina | 841 | $91,837 | $38 |
| Established patient problem focused exam of visual system | 397 | $84,367 | $80 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 288 | $33,233 | $90 |
| New patient visit (45+ min) | 209 | $25,504 | $122 |
| Photography of the retina | 368 | $20,978 | $44 |
| Compounded drug, not otherwise classified | 63 | $11,608 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 82 | $4,095 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 62 | $2,580 | $26 |
| 2d ultrasound scan of eye tissue and structures | 25 | $1,800 | $56 |
2018: 20 services
| Injection, aflibercept, 1 mg | 188 | $1,392,122 | None |
| Injection, ranibizumab, 0.1 mg | 80 | $536,764 | None |
| Established patient complete exam of visual system | 826 | $163,880 | $102 |
| Injection of drug into eye | 333 | $138,537 | $94 |
| Imaging of retina | 833 | $89,281 | $38 |
| Established patient problem focused exam of visual system | 354 | $66,508 | $77 |
| New patient visit (45+ min) | 214 | $27,008 | $126 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 210 | $20,588 | $80 |
| Compounded drug, not otherwise classified | 95 | $17,385 | None |
| Photography of the retina | 274 | $16,517 | $49 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $12,229 | $1,112 |
| Destruction of growth of retina using a laser | 12 | $5,805 | $484 |
| Destruction of leaking blood vessels of retina using laser | 14 | $4,873 | $287 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 11 | $2,666 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 53 | $2,412 | $21 |
| Examination of eye by ophthalmoscope with retinal drawing | 51 | $2,188 | $25 |
| 2d ultrasound scan of eye tissue and structures | 18 | $1,662 | $64 |
| Return visit (30+ min) | 18 | $1,119 | $59 |
| Short return visit (20+ min) | 11 | $641 | $53 |
| Short return visit | 11 | $267 | $24 |
2017: 17 services
| Injection, aflibercept, 1 mg | 174 | $1,210,462 | None |
| Injection, ranibizumab, 0.1 mg | 49 | $357,198 | None |
| Established patient complete exam of visual system | 814 | $148,915 | $100 |
| Injection of drug into eye | 315 | $122,389 | $91 |
| Imaging of retina | 835 | $91,693 | $37 |
| Established patient problem focused exam of visual system | 381 | $73,522 | $74 |
| New patient visit (45+ min) | 223 | $27,218 | $122 |
| Compounded drug, not otherwise classified | 117 | $21,639 | None |
| Photography of the retina | 207 | $16,245 | $62 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 158 | $14,015 | $72 |
| Destruction of growth of retina using a laser | 15 | $8,694 | $483 |
| Destruction of leaking blood vessels of retina using laser | 15 | $5,668 | $298 |
| Return visit (30+ min) | 28 | $2,593 | $89 |
| 2d ultrasound scan of eye tissue and structures | 19 | $2,312 | $83 |
| Examination of eye by ophthalmoscope with retinal drawing | 52 | $1,914 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 38 | $1,614 | $25 |
| Short return visit (20+ min) | 17 | $1,130 | $59 |
2016: 17 services
| Injection, aflibercept, 1 mg | 167 | $1,038,163 | None |
| Injection, ranibizumab, 0.1 mg | 42 | $326,412 | None |
| Established patient complete exam of visual system | 742 | $140,535 | $101 |
| Injection of drug into eye | 303 | $109,590 | $92 |
| Imaging of retina | 799 | $101,934 | $41 |
| Established patient problem focused exam of visual system | 374 | $79,532 | $75 |
| New patient visit (45+ min) | 243 | $30,580 | $126 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 139 | $28,494 | $99 |
| Compounded drug, not otherwise classified | 120 | $18,390 | None |
| Photography of the retina | 178 | $14,199 | $68 |
| Destruction of growth of retina using a laser | 20 | $10,027 | $456 |
| Destruction of leaking blood vessels of retina using laser | 13 | $5,010 | $278 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 18 | $3,625 | None |
| 2d ultrasound scan of eye tissue and structures | 25 | $3,495 | $87 |
| Examination of eye by ophthalmoscope with retinal drawing | 54 | $2,172 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 46 | $1,854 | $21 |
| Short return visit (20+ min) | 12 | $867 | $62 |
2015: 18 services
| Injection, aflibercept, 1 mg | 155 | $887,024 | None |
| Injection, ranibizumab, 0.1 mg | 48 | $315,317 | None |
| Established patient complete exam of visual system | 750 | $140,865 | $99 |
| Injection of drug into eye | 290 | $104,727 | $94 |
| Imaging of retina | 790 | $101,439 | $41 |
| Established patient problem focused exam of visual system | 330 | $56,443 | $75 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 133 | $29,628 | $100 |
| New patient visit (45+ min) | 221 | $29,018 | $131 |
| Destruction of leaking blood vessels of retina using laser | 16 | $17,469 | $919 |
| Destruction of growth of retina using a laser | 27 | $14,428 | $465 |
| Unclassified biologics | 102 | $12,843 | None |
| Photography of the retina | 156 | $12,613 | $67 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 23 | $5,540 | None |
| Compounded Drug, Not Otherwise Classified | 47 | $3,984 | $55 |
| 2d ultrasound scan of eye tissue and structures | 20 | $2,363 | $88 |
| Short return visit (20+ min) | 20 | $1,831 | $63 |
| Examination of eye by ophthalmoscope with retinal drawing | 32 | $1,373 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 28 | $1,018 | $23 |
2014: 18 services
| Injection, aflibercept, 1 mg | 136 | $747,396 | None |
| Injection, ranibizumab, 0.1 mg | 74 | $406,277 | None |
| Established patient complete exam of visual system | 749 | $145,977 | $99 |
| Injection of drug into eye | 313 | $107,085 | $90 |
| Imaging of retina | 789 | $104,626 | $41 |
| Established patient problem focused exam of visual system | 334 | $46,720 | $75 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 171 | $35,183 | $100 |
| New patient visit (45+ min) | 247 | $33,076 | $134 |
| Destruction of leaking blood vessels of retina using laser | 21 | $26,121 | $933 |
| Destruction of growth of retina using a laser | 34 | $20,523 | $477 |
| Unclassified biologics | 136 | $17,884 | None |
| Photography of the retina | 186 | $13,582 | $66 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 43 | $9,799 | None |
| 2d ultrasound scan of eye tissue and structures | 24 | $2,354 | $87 |
| Examination of eye by ophthalmoscope with retinal drawing | 60 | $2,049 | $23 |
| Short return visit (20+ min) | 20 | $960 | $44 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $830 | $25 |
| Imaging of optic nerve | 11 | $517 | $40 |
2013: 18 services
| Injection, aflibercept, 1 mg | 111 | $738,833 | None |
| Injection, ranibizumab, 0.1 mg | 122 | $619,216 | None |
| Established patient complete exam of visual system | 752 | $148,589 | $100 |
| Injection of drug into eye | 339 | $123,403 | $88 |
| Imaging of retina | 770 | $104,490 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 228 | $52,846 | $104 |
| Established patient problem focused exam of visual system | 303 | $37,605 | $74 |
| Destruction of growth of retina using a laser | 55 | $36,423 | $486 |
| Destruction of leaking blood vessels of retina using laser | 27 | $31,935 | $939 |
| New patient visit (45+ min) | 241 | $31,456 | $131 |
| Photography of the retina | 235 | $20,099 | $67 |
| Unclassified biologics | 137 | $18,937 | None |
| Removal of membrane of retina | 11 | $13,743 | $1,249 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 40 | $9,887 | None |
| 2d ultrasound scan of eye tissue and structures | 40 | $4,232 | $90 |
| Short return visit (20+ min) | 29 | $1,898 | $63 |
| Examination of eye by ophthalmoscope with retinal drawing | 51 | $1,281 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 41 | $1,041 | $25 |
Medicaid work
$281,134 in 2024
Medicaid paid $281,134 for 2,697 billed services this clinician did in 2024, up to 102 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 323 | $143,846 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 682 | $63,520 |
| Injection, faricimab-svoa, 0.1 mg | 155 | $52,593 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,008 | $12,544 |
| Return visit (30+ min) | 232 | $3,436 |
| Short return visit (20+ min) | 129 | $2,133 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 124 | $1,613 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 44 | $1,450 |
| 2024 | 2,697 | 8 | 102 | $281,134 |
| 2023 | 3,714 | 11 | 99 | $418,282 |
| 2022 | 3,571 | 10 | 109 | $481,864 |
| 2021 | 3,449 | 9 | 104 | $312,374 |
| 2020 | 3,107 | 7 | 88 | $278,629 |
| 2019 | 2,871 | 8 | 78 | $187,190 |
| 2018 | 2,292 | 9 | 79 | $114,980 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 655 | $275,843 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 919 | $101,982 |
| Injection, faricimab-svoa, 0.1 mg | 56 | $18,260 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,241 | $14,963 |
| Return visit (30+ min) | 301 | $2,331 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 94 | $1,663 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 159 | $1,121 |
| Short return visit (20+ min) | 224 | $831 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 36 | $704 |
| Injection, bevacizumab, 10 mg | 17 | $480 |
| New patient visit (45+ min) | 12 | $104 |
2022
| Aflibercept injection | 775 | $397,442 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 817 | $64,845 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,106 | $10,160 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 277 | $2,223 |
| Injection, bevacizumab, 10 mg | 64 | $2,106 |
| Return visit (30+ min) | 177 | $1,461 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 99 | $1,442 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 179 | $1,373 |
| New patient visit (45+ min) | 12 | $473 |
| Short return visit (20+ min) | 65 | $340 |
2021
| Aflibercept injection | 680 | $246,728 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 793 | $51,596 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 989 | $5,454 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 542 | $3,605 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 190 | $1,793 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 63 | $1,215 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 68 | $701 |
| Return visit (30+ min) | 81 | $687 |
| New patient visit (45+ min) | 43 | $595 |
2020
| Aflibercept injection | 541 | $222,778 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 698 | $42,951 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 823 | $4,522 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 475 | $4,335 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 385 | $2,891 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 74 | $581 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 111 | $570 |
2019
| Aflibercept injection | 338 | $128,128 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 582 | $45,446 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 482 | $4,235 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 728 | $3,051 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 184 | $1,858 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 325 | $1,826 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 190 | $1,336 |
| New patient visit (45+ min) | 42 | $1,311 |
2018
| Aflibercept injection | 231 | $71,599 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 463 | $34,435 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 758 | $3,087 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 460 | $2,905 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 238 | $1,508 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 57 | $646 |
| New patient visit (45+ min) | 26 | $450 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 47 | $269 |
| Compounded drug, not otherwise classified | 12 | $81 |
Drugs they prescribed that Part D paid
$50,254
Pharmacies billed $50,254 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 552) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
425 generic and 127 brand-name prescriptions · $50,254 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bromfenac | 77 | $11,199 | $145 |
| Xiidra | 11 | $7,379 | $671 |
| Brimonidine | 39 | $3,632 | $93 |
| Prednisolone Acetate | 42 | $1,479 | $35 |
| Diclofenac | 143 | $1,393 | $10 |
See all 11 drugs
| Bromfenac | 77 | $11,199 | $145 |
| Xiidra | 11 | $7,379 | $671 |
| Brimonidine | 39 | $3,632 | $93 |
| Prednisolone Acetate | 42 | $1,479 | $35 |
| Diclofenac | 143 | $1,393 | $10 |
| Neomycin-Polymyxin-Dexameth | 86 | $845 | $10 |
| Ketorolac Tromethamine | 19 | $493 | $26 |
| Latanoprost | 46 | $455 | $10 |
| Timolol Maleate | 20 | $424 | $21 |
| Dorzolamide | 11 | $156 | $14 |
| Dorzolamide-Timolol | 12 | $124 | $10 |
Year by year
| 2024 | 552 | 134 | 0% (0) | 23% | $50,254 |
| 2023 | 499 | 130 | 0% (0) | None | $52,605 |
| 2022 | 474 | 117 | 0% (0) | None | $53,881 |
| 2021 | 407 | 103 | 0% (0) | 55% | $55,864 |
| 2020 | 436 | 95 | None | 64% | $65,703 |
| 2019 | 530 | 120 | None | 65% | $72,187 |
| 2018 | 495 | 111 | None | 63% | $60,859 |
| 2017 | 516 | 102 | None | 61% | $65,522 |
| 2016 | 422 | 105 | None | 63% | $53,193 |
| 2015 | 380 | 105 | None | 55% | $45,668 |
| 2014 | 340 | 102 | 0% (0) | 59% | $41,039 |
| 2013 | 447 | 141 | None | 55% | $43,487 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Restasis | 13 | $15,865 | $1,220 |
| Bromfenac | 22 | $4,382 | $199 |
| Alphagan P | 13 | $3,300 | $254 |
| Brimonidine | 43 | $2,818 | $66 |
| Brimonidine Tartrate-Timolol | 14 | $2,609 | $186 |
| Prednisolone Acetate | 59 | $1,953 | $33 |
| Diclofenac | 118 | $1,444 | $12 |
| Neomycin-Polymyxin-Dexameth | 62 | $937 | $15 |
| Atropine Sulfate | 19 | $665 | $35 |
| Latanoprost | 31 | $644 | $21 |
| Ketorolac Tromethamine | 19 | $587 | $31 |
| Timolol Maleate | 26 | $476 | $18 |
| Dorzolamide | 11 | $340 | $31 |
2022: 11 drugs
| Prolensa | 19 | $6,818 | $359 |
| Brimonidine | 40 | $3,552 | $89 |
| Bromfenac | 13 | $2,145 | $165 |
| Prednisolone Acetate | 55 | $1,756 | $32 |
| Ketorolac Tromethamine | 31 | $1,601 | $52 |
| Diclofenac | 88 | $1,176 | $13 |
| Atropine Sulfate | 21 | $846 | $40 |
| Neomycin-Polymyxin-Dexameth | 38 | $567 | $15 |
| Latanoprost | 36 | $524 | $15 |
| Dorzolamide | 11 | $413 | $38 |
| Timolol Maleate | 27 | $380 | $14 |
2021: 10 drugs
| Combigan | 16 | $4,677 | $292 |
| Prolensa | 12 | $3,800 | $317 |
| Brimonidine | 35 | $2,417 | $69 |
| Prednisolone Acetate | 50 | $2,361 | $47 |
| Ketorolac Tromethamine | 29 | $1,403 | $48 |
| Diclofenac | 84 | $1,080 | $13 |
| Latanoprost | 30 | $768 | $26 |
| Atropine Sulfate | 16 | $750 | $47 |
| Neomycin-Polymyxin-Dexameth | 33 | $494 | $15 |
| Timolol Maleate | 15 | $251 | $17 |
2020: 12 drugs
| Ilevro | 28 | $9,448 | $337 |
| Prolensa | 27 | $8,663 | $321 |
| Alphagan P | 18 | $5,100 | $283 |
| Simbrinza | 23 | $4,063 | $177 |
| Brimonidine | 26 | $3,648 | $140 |
| Combigan | 14 | $2,953 | $211 |
| Prednisolone Acetate | 57 | $2,854 | $50 |
| Ketorolac Tromethamine | 41 | $2,260 | $55 |
| Diclofenac | 64 | $937 | $15 |
| Latanoprost | 29 | $934 | $32 |
| Timolol Maleate | 22 | $577 | $26 |
| Neomycin-Polymyxin-Dexameth | 29 | $501 | $17 |
2019: 16 drugs
| Ilevro | 42 | $12,098 | $288 |
| Nevanac | 11 | $8,416 | $765 |
| Prolensa | 26 | $7,202 | $277 |
| Restasis | 12 | $7,156 | $596 |
| Alphagan P | 28 | $5,605 | $200 |
| Simbrinza | 33 | $5,593 | $169 |
| Durezol | 22 | $4,598 | $209 |
| Azopt | 12 | $4,358 | $363 |
| Brimonidine | 23 | $2,734 | $119 |
| Prednisolone Acetate | 58 | $2,624 | $45 |
| Timolol Maleate | 22 | $2,151 | $98 |
| Combigan | 12 | $2,149 | $179 |
| Ketorolac Tromethamine | 43 | $1,734 | $40 |
| Latanoprost | 53 | $1,101 | $21 |
| Neomycin-Polymyxin-Dexameth | 52 | $778 | $15 |
| Diclofenac | 50 | $702 | $14 |
2018: 14 drugs
| Ilevro | 46 | $12,253 | $266 |
| Restasis | 17 | $10,931 | $643 |
| Prolensa | 14 | $4,184 | $299 |
| Simbrinza | 20 | $3,449 | $172 |
| Durezol | 17 | $3,301 | $194 |
| Alphagan P | 15 | $2,606 | $174 |
| Prednisolone Acetate | 61 | $2,571 | $42 |
| Brimonidine | 28 | $2,110 | $75 |
| Combigan | 11 | $2,077 | $189 |
| Ketorolac Tromethamine | 39 | $1,597 | $41 |
| Timolol Maleate | 26 | $1,484 | $57 |
| Latanoprost | 65 | $1,400 | $22 |
| Neomycin-Polymyxin-Dexameth | 55 | $864 | $16 |
| Diclofenac | 34 | $439 | $13 |
2017: 16 drugs
| Restasis | 22 | $12,345 | $561 |
| Nevanac | 30 | $12,094 | $403 |
| Alphagan P | 41 | $7,182 | $175 |
| Durezol | 21 | $4,355 | $207 |
| Simbrinza | 17 | $3,249 | $191 |
| Brimonidine | 24 | $3,115 | $130 |
| Ilevro | 12 | $2,929 | $244 |
| Travatan Z | 16 | $2,891 | $181 |
| Timolol Maleate | 28 | $2,656 | $95 |
| Prednisolone Acetate | 47 | $2,009 | $43 |
| Combigan | 12 | $1,779 | $148 |
| Latanoprost | 74 | $1,145 | $15 |
| Diclofenac | 55 | $804 | $15 |
| Ketorolac Tromethamine | 17 | $591 | $35 |
| Neomycin-Polymyxin-Dexameth | 40 | $570 | $14 |
| Dorzolamide-Timolol | 11 | $226 | $21 |
2016: 13 drugs
| Nevanac | 34 | $12,780 | $376 |
| Restasis | 17 | $8,085 | $476 |
| Alphagan P | 32 | $5,764 | $180 |
| Brimonidine | 21 | $3,242 | $154 |
| Simbrinza | 21 | $2,763 | $132 |
| Durezol | 11 | $2,288 | $208 |
| Travatan Z | 11 | $1,838 | $167 |
| Prednisolone Acetate | 29 | $1,788 | $62 |
| Timolol Maleate | 24 | $1,751 | $73 |
| Neomycin-Polymyxin-Dexameth | 44 | $803 | $18 |
| Diclofenac | 36 | $693 | $19 |
| Latanoprost | 57 | $639 | $11 |
| Ketorolac Tromethamine | 11 | $252 | $23 |
2015: 11 drugs
| Nevanac | 29 | $13,265 | $457 |
| Restasis | 18 | $10,346 | $575 |
| Timolol Maleate | 28 | $2,594 | $93 |
| Durezol | 14 | $2,383 | $170 |
| Alphagan P | 15 | $2,103 | $140 |
| Brimonidine | 22 | $1,775 | $81 |
| Lumigan | 11 | $1,493 | $136 |
| Neomycin-Polymyxin-Dexameth | 73 | $1,201 | $16 |
| Prednisolone Acetate | 21 | $897 | $43 |
| Latanoprost | 45 | $463 | $10 |
| Diclofenac | 27 | $336 | $12 |
2014: 12 drugs
| Restasis | 27 | $9,363 | $347 |
| Bromfenac | 27 | $9,279 | $344 |
| Travatan Z | 16 | $3,337 | $209 |
| Nevanac | 11 | $3,180 | $289 |
| Azopt | 14 | $2,182 | $156 |
| Alphagan P | 19 | $1,959 | $103 |
| Combigan | 13 | $1,369 | $105 |
| Timolol Maleate | 15 | $1,072 | $71 |
| Latanoprost | 61 | $881 | $14 |
| Neomycin-Polymyxin-Dexameth | 36 | $640 | $18 |
| Prednisolone Acetate | 11 | $267 | $24 |
| Diclofenac | 19 | $247 | $13 |
2013: 14 drugs
| Restasis | 23 | $8,120 | $353 |
| Nevanac | 25 | $6,527 | $261 |
| Bromday | 17 | $4,431 | $261 |
| Combigan | 31 | $3,094 | $100 |
| Bromfenac | 17 | $3,087 | $182 |
| Travatan Z | 16 | $2,931 | $183 |
| Alphagan P | 26 | $2,580 | $99 |
| Azopt | 18 | $2,344 | $130 |
| Durezol | 15 | $1,878 | $125 |
| Neomycin-Polymyxin-Dexameth | 56 | $976 | $17 |
| Latanoprost | 46 | $948 | $21 |
| Diclofenac | 35 | $799 | $23 |
| Prednisolone Acetate | 27 | $695 | $26 |
| Timolol Maleate | 31 | $574 | $19 |
Money from drug and device companies
$271 in 2025
| 2025 | 6 | 9 | None | $271 |
| 2024 | 7 | 10 | None | $394 |
| 2023 | 9 | 22 | None | $1,010 |
| 2022 | 5 | 10 | None | $367 |
| 2021 | 5 | 8 | None | $395 |
| 2020 | 2 | 2 | None | $40 |
| 2019 | 7 | 10 | None | $1,091 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Vabysmo | $69 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $67 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $47 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $33 | 1 payment
|
| Harrow Eye | Triesence | $30 | 1 payment
|
| Astellas Pharma US | Izervay | $25 | 1 payment
|
See all 9 published payments
| Genentech USA | Meals · 2025-12-12 | Vabysmo | $35 |
| Astellas Pharma US | Meals · 2025-11-24 | Izervay | $25 |
| Regeneron Pharmaceuticals | Meals · 2025-10-31 | Eylea Hd | $20 |
| Regeneron Healthcare Solutions | Meals · 2025-10-01 | Eylea Hd | $37 |
| Harrow Eye | Meals · 2025-09-17 | Triesence | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-05-28 | Eylea Hd | $30 |
| Regeneron Pharmaceuticals | Meals · 2025-05-09 | Eylea Hd | $26 |
| Genentech USA | Meals · 2025-04-16 | Vabysmo | $34 |
| ANI Pharmaceuticals | Meals · 2025-02-25 | Purified Cortrophin Gel | $33 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $394
| RxSight | Rxsight Contact Lens | $114 | 1 payment
|
| Genentech USA | Vabysmo | $100 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $71 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $33 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $29 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea Hd | $24 | 1 payment
|
| Alimera Sciences | Yutiq | $23 | 1 payment
|
2023: $1,010
| Genentech USA | Vabysmo | $278 | 5 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $194 | 7 payments
|
| Apellis Pharmaceuticals | Syfovre | $158 | 3 payments
|
| Acclarent | Acclarent Navwire | $145 | 1 payment
|
| Alcon Vision | Constellation | $113 | 1 payment
|
| Alimera Sciences | Iluvien | $45 | 2 payments
|
| Abbvie | Ozurdex | $30 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $26 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $22 | 1 payment
|
2022: $367
| EyePoint Pharmaceuticals US | Dexycu | $161 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $87 | 3 payments
|
| Genentech USA | Vabysmo | $77 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea | $23 | 1 payment
|
| Alimera Sciences | Iluvien | $18 | 1 payment
|
2021: $395
| Genentech USA | Lucentis | $280 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $59 | 2 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $22 | 1 payment
|
| Optos | Panoramic Ophthalmoscope | $21 | 1 payment
|
| Alimera Sciences | Iluvien | $13 | 1 payment
|
2020: $40
| Genentech USA | Lucentis | $22 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $18 | 1 payment
|
2019: $1,091
| Allergan | None | $417 | 1 payment
|
| Alcon Vision | Constellation | $198 | 2 payments
|
| Genentech | Lucentis | $150 | 1 payment
|
| Genentech USA | Lucentis | $144 | 2 payments
|
| Hoffmann-La Roche | Non-Covered Product | $107 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $53 | 2 payments
|
| Alimera Sciences | Iluvien | $22 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Aflibercept 8mg in Rvo · 2024 | Their institution | $184,999 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 Mg in Macular Edema Secondary To Retinal Vein Occlusion · 2025 | Their institution | $94,947 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2021 | Their institution | $49,333 |
| Genentech, Inc. · A Phase 1 Sad MD in Diabetic Macular Edema · 2025 | Their institution | $43,829 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2024 | Their institution | $19,963 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2019 | Their institution | $16,787 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay865321, Hd 8mg, Amd - Ph 3 · 2022 | Their institution | $13,973 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay865321 Hd 8mg Amd - Ph 3 · 2021 | Their institution | $13,857 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay865321, Hd 8mg, Amd - Ph 3 · 2023 | Their institution | $12,280 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2022 | Their institution | $11,135 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2020 | Their institution | $5,759 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 Mg Aflibercept in Participants With Macular Edema Following Retinal Vein Occlusion · 2025 | Their institution | $5,000 |
| Regeneron Pharmaceuticals, Inc. · Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Neovascular Age-Related Macular Degeneration (Namd) and Diabetic Macular Edema (Dme) Treated With Aflibercept 8 Mg in the United States · 2025 | Their institution | $5,000 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3b Single-Arm Study of Aflibercept 8 Mg in Participants With Neovascular Age-Related Macular Degeneration (Namd) Or Diabetic Macular Edema (Dme) · 2025 | Their institution | $5,000 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2019 | This clinician | $2,287 |
| Bayer Healthcare Pharmaceuticals Inc. · Aflibercept 8mg in Rvo · 2023 | Their institution | $92 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053306381
- Licence
- CA G26383California G26383: Current · expires 2027-01-31
- Trained
- Stanford University School of Medicine, 1992
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G782191
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 2485 Hospital Dr, Orchard Pavilion Ste 200, Mountain View, CA, 94040
- NPI first listed
- 2005-09-13
- NPI last updated
- 2017-12-14
This is when the NPI record was last certified, not a medical board exam.